Summary. In addition to their usual diet, nine Type I (insulin-dependent) diabetic men and ten male control subjects took 20 g d,a-tocopheryl acetate enriched evening primrose oil (14.45 g 18:2c, co6, 1.73 g 18:3c, co6, 400mg d, cr-tocopheryl acetate) daily for one week. At start, diabetic patients had more 14:0, 15:0 and 18:2c, co6, and less 16:0, 16:1c, co7, 18:tc, co7, 18:3c,co6, 20:3c, co9, 20:3c, co6, 20:4c, co6 and 22:6c, co3 in plasma, erythrocytes and/or platelets. Furthermore, they had lower 16: lc, co7/16: 0, 18 : lc,~o7/16: 0, and 20: 4c, o~6/20: 3c, co6 ratios and a higher 20: 3c, co6/18 : 3c,~o6 ratio. In diabetic patients, a-tocopherol levels in erythrocytes were lower, whereas those in plasma were normal. In both groups, oil intake changed fatty acid profiles. Most markedly, 20:3c, co6 increased, whereas the ratios 20:3c, co6/ 18:3c, co6 and 20:4c, co6/20:3c,r decreased. 20:4c, co6 increased in control subjects, but not in diabetic patients. Erythrocytes and platelets responded differently in their fatty acid profiles, a-tocopherol rose in plasma and, although less for diabetic patients, in erythrocytes. In diabetic patients as well as in control subjects, erythrocyte count, haemoglobin level, mean corpuscular haemoglobin content and concentration increased and glycosylated haemoglobin percentage decreased without an apparent decline in blood glucose levels. Plasma fl-thromboglobulin and platelet factor 4 decreased, especially in diabetic patients. In conclusion, diabetic patients had abnormal fatty acid pattems, suggesting an impaired A 9, A 6 and A 5 desaturation and an enhanced chainelongation, and had lower erythrocyte a-tocopherol levels; and short-term high dose intake of evening primrose oil increased 20:3c, c06 in both groups, but 20:4c, co6 only in control subjects, gave fatty acid responses which were different for erythrocytes and platelets, enhanced erythropoiesis, and lowered indices of in vivo platelet activation.
Certain dietary fatty acids have a favourable influence on the pathogenesis of the long-term complications of diabetes mellitus. For example, intake of sardine oil normalises lowered membrane fluidity of erythrocytes [1] and use of cod-liver oil [2] or linoleic acid (18:2c, co6) enriched diet [3] corrects disturbed platelet aggregation. Both oils are rich in eicosapentaenoic acid (20: 5c, co3 ) and docosahexaenoic acid (22: 6c, co3 ). Furthermore, a 18:2c, co6-rich diet was reported to inhibit the progression of diabetic retinopathy [4, 5] ; and supplementation with evening primrose oil (EPO), which especially contains gamma-linolenic acid (18:3c, co6 ) in addition to a large amount of 18:2c,~o6, has been suggested to improve diabetic neuropathy [6] .
Abnormal fatty acid compositions are found in plasma lipids [7, 8] , erythrocytes [7, 8] , platelets [8, 9] and adipose tissue [10] of patients with Type I (insulindependent) diabetes mellitus. An increased level of 18:2c, co6 [8, 9] along with decreased levels of its metabolites 18:3c, co6 [7, 9] and dihomo-gamma-linolenic acid (20:3c, co6) [8, 9] suggests an impaired activity of the enzyme A 6 desaturase, as has been shown in in vitro and in vivo experiments with insulin deficient rats [11, 12] .
The present study was designed to evaluate the effect of dietary 18:3c, co6 supplementation on the fatty acid composition of plasma-, erythrocyte-and platelet lipids from Type I diabetic patients by administration of EPO. Additionally, plasma-and erythrocyte a-tocopherol levels were determined, as patients with Type 1 diabetes mellitus are reported to have abnormalities in vitamin E metabolism [13] and the EPO containing capsules were enriched with a-tocopheryl acetate. To minimise potential influences due to, amongst others, changes in diabetic control, dietary habits and life style, we performed a short-term supplementation study with a relatively high dose of the oil. 
Subjects and methods

Diabetic patients and control subjects
Nine Type 1 diabetic men of whom the individual characteristics are shown in Table 1 , and ten apparently healthy male members of the hospital staff (aged 24-54 years, median 30 years) were studied. All diabetic patients were ketosis-prone. None of them had nephropathy, proliferative retinopathy or other relevant disease. The groups did not differ for body weight (control subjects: 65. At the end of the EPO use period, a small increase in body weight was found in the group of control subjects (median increase 0.4 kg, p < 0.05). The protocol was approved by the medical ethical committee of the hospital. Written informed consent was obtained from every participant.
Methods
At the start and at the end of the EPO intake period, and at one week thereafter, venous blood samples with and without EDTA and heparine as anticoagulant were collected without occlusion 1-3 h after breakfast. On the day before blood sampling, the diabetic patients collected fingerprick samples for blood glucose measurements at 03.00 hours, 07.00 hours (fasting), 1.5 h after breakfast, 11.00 hours, 1.5 h after lunch, 17.00 hours, 1.5 h after dinner, and at 23.00 hours.
EDTA-anticoagulated blood served for the isolation of plateletpoor plasma, platelets and erythrocytes and for the preparation of blood cell profiles that were made by a Coulter Counter Model Splus IV (Coulter Electronics Ltd., Luton, Bedfordshire, UK) at least 1 h after venipuncture [14] . Ten ml samples were centrifuged at 250 g for 10 rain. The platelet-rich plasma was collected and recentrifuged for 10 min at 1500 g. The supematant (platelet-poor plasma) was removed and the platelet-pellet was washed three times with 2 ml of 0.9% sodium chloride solution. The erythrocytes were washed three times with 5 ml 0.9% sodium chloride solution. After each centrifugation at 800 g for 10 min, the buffy coat was removed as completely as possible. The erythrocytes were finally resuspended to a haematocrit of about 50%, and counted in a Coulter Counter Model Splus IV. Fatty acid profiles of plasma, the erythrocyte suspension (approximately 50%) and the whole platelet-petlet were performed by a previously described capillary gas chromatographic method [15] , using an apolar stationary phase. For technical reasons 23:0, 24:0, and 24:1c, w9 could not reliably be analysed, a-tocopherol in plasma and vitamin E in erythrocyte suspension were determined by high performance liquid chromatography with fluorescence detection [16, 17] . As the qualitatively and quantitatively major part of vitamin E in erythrocytes is c~-tocopherol [18] , vitamin E is referred to in the text as a-tocopherol./%thromboglobulin and platelet factor 4 were measured in platelet-poor plasma by radioimmunoassay (Amersham, Buckinghamshire, UK, and Abbott Laboratories, North Chicago, Ill, USA, respectively). Fmctosamine concentrations were determined in plasma [191 with a Multistat III (Instrumentation Laboratory, Spokane, Wash, USA). The reagent was carbonate buffer (0.1 mol/1, pH 10.35) containing 0.25 mmol/1 nitroblue tetrazolium chloride. Protein-based standards and control sera were obtained from Instruchemie BV, Hilversum, The Netherlands.
Heparine-anticoagulated blood was used for the measurement of glycosylated haemoglobin by a colorimetric method [20] .
Serum was prepared from venous blood by centrifugation at 1500 g for 10 min. Serum parameters of renal and liver function, and the concentrations of cholesterol and triglycerides were measured by a Sequential Multiple Analyzer Plus Computer (SMA-C, Technicon, Tarrytown, NY, USA). Serum levels of free T4 and thyroid stimulat= ing hormone were determined by radioimmunoassay tests (Amersham International plc, Amersham, UK).
Statistical analysis
Statistical analyses were performed by Wilcoxon two sided rank sum test for paired and unpaired data; pvalues~0.05 were considered significant. Linear regression line parameters were calculated according to Deming [21] .
Results
Fatty acid compositions
The fatty acid profiles before, at the end of one week EPO intake and at one week thereafter are given in Table 2 . Relative amounts (median values) of plasma fatty acids from Type I diabetic men and healthy male control subjects at the start (A), at the end of a one week period of evening primrose oil intake (B), and at one week thereafter (C)
Fatty
Diabetic patients (n = 9) acids Control subjects (n = 10) Table 2 , for erythrocytes in Table 3 and for platelets in for relative amounts r=-0.59, 0.05<p< 0.10), as well as between glycosylated haemoglobin levels and plasma 18:2c, co6 levels (r=-0.66, 0.05< p < 0A0). The median values of desaturase and chainelongation product/precursor ratios and the essential fatty acid status ratio 20:3c, co9/20:4c, o96 [22] in plasma, erythrocytes and platelets are shown in Table 5 .
~z-tocopherol
The individual ct-tocopherol levels in erythrocytes before, at the end of one week EPO intake and at one week thereafter are depicted in Figure I (median values for diabetic patients: 4.17 to 4.72 to 4.63 nmol/101~ cells, and for control subjects: 5.47 to 6.86 to 5.95 nmol/101~ cells). The absolute and relative increases at the end of one week EPO use were less in the diabetic patients than in the control subjects (p < 0,01 and p < 0.05, respectively). The a-tocopherot con-centration in plasma was increased at the end of one week EPO intake and returned to base-line level at one week thereafter (median values for diabetic patients: 23 to 47 (p < 0.01) to 23 lxmol/l (p < 0.01), and for con- 
Peripheral blood cell profiles
The median values in erythrocyte counts, its indices and reticulocyte promillages are given in Table 6 . Erythrocyte a-tocopherol content is correlated with mean corpuscular volume (r=0.56, 0.05 <p <0.10), mean corpuscular haemoglobin and mean corpuscular haemoglobin concentration in the control group (Fig.2) , but not in the diabetic group (r=-0.04, r=-0.15, r = -0.14, respectively). t~.50. Table 5 . Median values of desaturase and chain-elongation product/precursor ratios and essential fatty acid status parameters in plasma, erythrocytes and platelets from Type 1 diabetic men and healthy male control subjects at the start (A), at the end of a one week period of evening primrose oil intake (B), at one week thereafter (C)
Compartments
Molar ratios Diabetic patients (n = 9) Control subjects (n = 10) In the diabetic group, mean platelet volume increased after one week EPO use and decreased thereafter (median values: 9.0 to 9.3 (p < 0.05) to 9.1 fl (p < 0.05). In the control group, polymorphonuclear leukocyte count was increased at one week after EPO intake (median values: 3.0 to 3.6 to 3.4 x 109/1 (p < 0.02 versus at the start)). No other changes were found for platelet counts, its indices, total leukocyte counts and differentiations.
Platelet function
Platelet factor 4 level in plasma was decreased after one week EPO use and returned to base-line level at one week thereafter (median values for diabetic patients: 18.6 to 8.9 (p <0.02) to 16.5 ng/1 (p <0.01), and for control subjects: 16.1 to 9.3 (0.05<p<0.10) to 13.7 ng/1). Plasma fl-thromboglobulin demonstrated a similar pattern. Its changes were only significant in the diabetic group (median values for patients: 55.3 to 34.4 (p <0.05) to 51.6 ng/1 (p <0.01) and for control subjects: 52.9 to 40.1 to 48.2 ng/l). At the start of the study, no differences were found in these two platelet function parameters between the diabetic patients and the control subjects.
Parameters of diabetic control
Parameters of diabetic control are given as median values in Table 6 .
Other laboratory tests
At the start of the study, differences between the diabetic and the control group were demonstrated for the i Table 6 . Median values of some-haematological tests and parameters of diabetic control from Type I diabetic men and healthy male control subjects at the start (A), at the end of a one week period of evening primrose oil intake (B) and at one week thereafter (C)
Diabetic patients (n = 9) Control subjects (n = 10) The serum concentration of thyroid stimulating hormone did not differ between both groups. From one week of EPO use to one week thereafter a slight decrease in serum levels was observed for total protein in both groups (median value in the group of the patients from 66 to 65 g/l, p < 0.02, and in that of the control subjects from 71 to 69 g/l, p < 0.05), and for albumin and alkaline phosphatase in the diabetic patients (median from 43 to 42 g/l, p < 0.05, and from 80 to 73 U/l, p < 0.02, respectively).
Discussion
This study shows that Type I diabetic men differ from healthy male control subjects for plasma and cellular fatty acid patterns and erythrocyte a-tocopherol levels. Furthermore, it describes the effects of short-term intake of a considerable amount of a-tocopherol enriched EPO on a variety of biochemical tests and on parameters for erythropoiesis, platelet function and diabetic control in both groups.
Fatty acids
Before EPO supplementation, the group of Type 1 diabetic patients had abnormal fatty acid patterns in plasma, erythrocytes and platelets (Table 2) , consistent with those reported in the literature [7] [8] [9] . These abnormal profiles as well as the abnormal desaturase and chain-elongation product/precursor ratios (Table 5) may reflect diminished activity of the A9, A6 and A5 desaturase enzymes due to insulin deficiency, as has been shown in in vitro and in vivo studies in diabetic rats [11, 12, 23, 24] . The elevated 18:2c, co6 content in all three compartments might be due to the impaired activity of A6 desaturase by hormonal derangement~ However, the lower plasma 20: 3c, co9/20: 4c, co6 ratio, that is considered to be a reliable parameter of the es, sential fatty acid status under normal circumstances [22] , but not in certain pathological conditions [25] [26] [27] , points to a possibly higher dietary 18:2c,o~6 intake in the diabetic group. In contrast to others [8] , we found a negative correlation between erythrocyte 18:2c, co6 contents and glycosylated haemoglobin levels, for which we have no explanation. Evening primrose oil contains a high amount of 18:2c, co6 (72.40 tool/100 tool) and some 18:3c, co6 (8.74 mol/100 mol). The latter is normally a quantita~ tively minor dietary constituent. Roughly estimated, the total dietary intake of 18:2c,~o6 was doubled by the quantity of the EPO supplementation, used in our study. Conceivably, the itntake of this oil led to an increase of both fatty acids and total w6 fatty acids, and to a fall in the 20:3c, oa9/20:4c, co6 ratios. The level of 20:3c, o96 increased in all compartments of both groups, suggesting partial metabolisation of the supplemented 18:3c, co6 by chain-elongation, as has also been found in other studies in man [28] [29] [30] . However, an increase of 20:4c,096 was only found in the plasma compartment of the control group. This finding, along with the decrease in the chain-elongation product/precursor ratio 20:3c,096/18:3c,096 and the A 5 desaturase product/precursor ratio 20:4c,096/20: 3c,096, found in all compartments in both diabetic patients and control subjects, points to the probable existence of regulatory mechanisms, that maintain tissue 20:4c, 096 content constantly. This hypothesis is consistent with data from studies in animals with essential fatty acid deficiency [31] , in man during different feeding regimens [32] [33] [34] and in several human pathological conditions [27, 35] . Apparently, the lowered 20:4c,096 level in plasma and erythrocytes in diabetic patients cannot be corrected by EPO administration. Likewise, supplementation by 6 g EPO daily during 8 weeks in Type 2 (non-insulin-dependent) diabetic patients, leading to an even larger increase of 20: 3c,096 in erythrocytes and platelets than was seen in our study, did not augment the 20:4c,096 level in these cells [29] . The refractoriness of 20:4c,096 to oral supplementation with its 096 precursors in diabetes meUitus has also been shown by an experiment in which daily intake of I g 20:3c,096 for 3 weeks enhanced 20:4c,096 content in erythrocytes from healthy volunteers, but not in those from Type 1 diabetic patients [36] . However, 20:4c,096 deficiency in tissue lipids of genetically diabetic mice was shown to be corrected by dietary EPO supplementation [37] . Therefore, it seems important to study the effect of long-term supplementation with 18:3c,096 in high doses, for which administration either as a crude oil with a complex fatty acid composition or in a highly purified form, may theoretically differ [38] . As 20:4c,096 only increased in the plasma compartment of the control group, it would also be interesting to determine the fatty acid compositions of the individual lipid fractions, such as phospholipids and cholesterylesters. It is noteworthy that improvement of diabetic control results in a 20:4c, o6 increase in plasma [7, 39] , erythrocytes [7, 39] and platelets [40] . Therefore, an attempt to correct low 20:4c,096 levels by administration of 18:3c,096 might only be useful for those patients in whom optimal diabetic control appears impossible.
EPO intake induced changes in fatty acid profiles which differ between erythrocytes and platelets. At one week after discontinuation of EPO use, most fatty acids in platelets were returning to their base-line values, whereas those in erythrocytes continued to alter. This difference is most probably explained by the higher turnover rate of platelets compared with erythrocytes (mean survival rate normally about 10days and 120 days, respectively), and the relatively slow equilibration of about 4-6 weeks [32] between dietary fatty acids and erythrocytes fatty acids as effected by continuous exchange of lipids between plasma and erythrocytes [41] . Furthermore, the cell species differ in their fatty acid response, especially for 14:0, 16:0, total saturated fatty acids, 22:4c,096, 22: 5c,093, and total o93 fatty acids in the control group. Such a difference in response was not noted in human studies with longterm administration of cod-liver oil [42] [43] [44] .
Except for 22:0 and 22:4c,096 in erythrocytes, the fatty acid compositions of the diabetic and the control group changed in the same direction, notwithstanding the fact that insulin deficiency causes profound disturbances in fatty acid metabolism in animals, such as a decline in de novo synthesis [23, 45] and desaturation of fatty acids [11, 12, 23, 24] , an acceleration of their chain-elongation and the promotion of lipolysis and fatty acid oxidation [46] .
It should be noted that blood samples were taken 1-3 h after breakfast. The data on the plasma fatty acid composition and serum lipids should therefore be interpreted with caution.
a-tocopherol
In the diabetic group, the ct-tocopherol level in erythrocytes was found to be abnormally low (Fig.l) , whereas that in plasma appeared to be normal. A similar discrepancy has been shown between platelets and plasma [13] . The reason for the decreased intracellular a-tocopherol levels is unknown. Theoretically, two explanations are possible. The delivery of a-tocopherol from the plasma compartment to the cells might be disturbed and/or intracellular a-tocopherol consumption might be enhanced. It is notable that in plasma of diabetic patients free radical activity seems to be increased [47] , while plasma a-tocopherol is protected against oxidation by protein binding [48] .
It is tempting to speculate, that the lowered 22:6c, o93 level in erythrocytes of the diabetic group, as also found in a previous study [7] , may be caused by increased lipid peroxidation and/or hampered A4 desaturation due to an a-tocopherol deficit [49] .
Erythropoiesis
The supplementation with EPO, which corresponded with an approximately 40-fold higher a-tocopherol intake than the estimated Dutch consumption [50], induced an increase in erythrocyte count, haemoglobin level, mean corpuscular haemoglobin (MHC) and mean corpuscular haemoglobin concentration (MCHC) ( Table 6 ), suggesting an augmentation of erythrocyte production as well as haemoglobin synthesis. The assumption of enhanced erythropoiesis concurs with the finding of a decline in glycosylated haemoglobin percentage in both groups [51] , which took place without apparent changes in other parameters of diabetic control (blood glucose levels in patients and control subjects, plasma fructosamine levels in patients; see Table 6 ).
It is a matter of speculation, which compound(s) in the oil induced these changes. MCH and MCHC appeared to be strongly correlated with erythrocyte a-tocopherol content in the normal group (Fig. 2) . One of the possible reasons for this relation could be the stimulatory function of vitamin E in the regulation of haem biosynthesis, presumably by controlling the mechanisms of induction and repression of fi-aminolevulinic acid synthetase [52] . The existence of an erythropoietic effect of a-tocopherol is, however, disputed [52, 53] .
Platelet function
fl-Thromboglobulin and platelet factor 4 are constituents of the platelet a-granule contents. Their concentrations in plasma are regarded as useful indicators of in vivo platelet activation and release reaction [54] . The plasma levels are influenced by dietary fatty acids [55] [56] [57] . EPO intake caused a decrease in the plasma levels of both compounds, which was most pronounced in the diabetic group. This result confirms the finding of another study in which a daily intake of 4.8 g EPO during 6 weeks by Type 1 diabetic patients also led to a decrease in/%thromboglobulin [56] . As herein no effects were seen on either prostaglandin E1 or thromboxane B2 generation by platelets, the observed change in platelet function is rather believed to result from alterations in membrane fatty acid composition, and therefore in membrane functioning, than from modifications in prostaglandin biosynthesis [56] . Some effect from a-tocopherol cannot be ruled out as vitamin E supplementation in Type 1 diabetic patients diminishes platelet aggregation in vitro [58] .
This study proposes that Type 1 diabetic patients have abnormal fatty acid patterns, suggesting an impaired A9, A6 and A5 desaturation and an enhanced chain-elongation. When compared with healthy control subjects, they have lower a-tocopherol levels in erythrocytes, which warrants further investigation. A short-term high dose EPO intake increased 20:3c, c06 in both diabetic patients and control subjects, but 20: 4c, co6 only in control subjects. This indicates a possible refractoriness of 20:4c, c06 in diabetes mellitus to dietary intervention. EPO use lowered plasma levels of the platelet release parameters/~-thromboglobulin and platelet factor 4, especially in the diabetic group.
